The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years. Additionally, the company is backed with venture capital in a seed round to advance the research and further develop the product for clinical validation.

Medical Devices

Dopavision

Mark Wuttke

Dr. Tim Schilling

Gabriela Burian

Vicky Gravia

Hamed Bahmani

Stefan Zundel

Andreas Balser

��

CEO and Executive Team

About

Team members

Other teams at Dopavision

Scientific and Medical Consulting

Leadership Team

Product and Design Team

��������